DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Custirsen is an investigational drug.
There have been 12 clinical trials for Custirsen. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are OncoGenex Technologies, NCIC Clinical Trials Group, and Teva Pharmaceutical Industries.
Recent Clinical Trials for Custirsen
|Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization||Teva Pharmaceutical Industries||Phase 1|
|Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization||OncoGenex Technologies||Phase 1|
|A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer||OncoGenex Technologies||Phase 3|